Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan
OBJECTIVES: To assess whether switching patients with suboptimally controlled pulmonary arterial hypertension from bosentan or ambrisentan to macitentan would improve six-minute walk test (6MWT) distance and World Health Organization functional class. METHODS: This was a retrospective cohort analysi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567785/ https://www.ncbi.nlm.nih.gov/pubmed/30975046 http://dx.doi.org/10.1177/0300060519840130 |